Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.08 USD
2.42 M USD
0.00 USD
3.70 M
About Citius Oncology, Inc.
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CTOR is 1.09 USD — it has increased by 8.33% in the past 24 hours. Watch Citius Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Citius Oncology, Inc. stocks are traded under the ticker CTOR.
CTOR stock has fallen by −4.59% compared to the previous week, the month change is a 4.52% rise, over the last year Citius Oncology, Inc. has showed a −90.04% decrease.
We've gathered analysts' opinions on Citius Oncology, Inc. future price: according to them, CTOR price has a max estimate of 3.00 USD and a min estimate of 3.00 USD. Watch CTOR chart and read a more detailed Citius Oncology, Inc. stock forecast: see what analysts think of Citius Oncology, Inc. and suggest that you do with its stocks.
CTOR reached its all-time high on Aug 6, 2024 with the price of 49.00 USD, and its all-time low was 0.85 USD and was reached on Nov 25, 2024. View more price dynamics on CTOR chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CTOR stock is 11.32% volatile and has beta coefficient of −2.19. Track Citius Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Citius Oncology, Inc. there?
Today Citius Oncology, Inc. has the market capitalization of 74.16 M, it has decreased by −6.00% over the last week.
Yes, you can track Citius Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Citius Oncology, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
CTOR earnings for the last quarter are −0.08 USD per share, whereas the estimation was −0.08 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Citius Oncology, Inc. earnings.
Citius Oncology, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CTOR net income for the last quarter is −21.89 M USD, while the quarter before that showed 252.46 K USD of net income which accounts for −8.77 K% change. Track more Citius Oncology, Inc. financial stats to get the full picture.
No, CTOR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CTOR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Citius Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Citius Oncology, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Citius Oncology, Inc. stock shows the buy signal. See more of Citius Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.